Cobicistat, darunavir, emtricitabine, and tenofovir and Propafenone
Determining the interaction of Cobicistat, darunavir, emtricitabine, and tenofovir and Propafenone and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Talk to your doctor before using propafenone together with cobicistat. Combining these medications may significantly increase the blood levels and effects of propafenone. This can increase the risk of serious side effects such as irregular heart rhythm and other cardiovascular problems. You may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. Contact your doctor if your condition changes or you experience increased side effects. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR CLOSELY: Coadministration with cobicistat may significantly increase the plasma concentrations of certain antiarrhythmic agents such as amiodarone, bepridil, disopyramide, flecainide, propafenone, and quinidine. The mechanism involves inhibition of CYP450 2D6 (flecainide, propafenone) and/or 3A4 (amiodarone, bepridil, disopyramide, quinidine) metabolism, as cobicistat is a potent inhibitor of both isoenzymes. The interaction has not been specifically studied, but could conceivably lead to serious and/or life-threatening reactions including cardiac arrhythmias and other toxicities if levels are significantly increased. The use of these antiarrhythmic agents has been associated with dose-related prolongation of the QT interval, thus elevated plasma levels may potentiate the risk of ventricular arrhythmias such as ventricular tachycardia and torsade de pointes as well as cardiac arrest and sudden death.
MANAGEMENT: Caution is advised if cobicistat must be used concomitantly with antiarrhythmic agents that are primarily metabolized by CYP450 2D6 and/or 3A4. Pharmacologic response and plasma antiarrhythmic drug levels should be monitored more closely whenever cobicistat is added to or withdrawn from therapy, and the antiarrhythmic dosage adjusted as necessary.
- "Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov)." Gilead Sciences, Foster City, CA.
Generic Name: cobicistat / darunavir / emtricitabine / tenofovir alafenamide
Brand name: Symtuza
Synonyms: Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide
Generic Name: propafenone
Brand name: Rythmol, Rythmol SR
Synonyms: n.a.
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Cobicistat, darunavir, emtricitabine, and tenofovir-Propafenone Extended Release Capsule
- Cobicistat, darunavir, emtricitabine, and tenofovir-Propafenone Hydrochloride
- Cobicistat, darunavir, emtricitabine, and tenofovir-Propafenone Sustained-Release Capsules
- Cobicistat, darunavir, emtricitabine, and tenofovir-Propafenone Tablets
- Cobicistat, darunavir, emtricitabine, and tenofovir-Propantheline
- Cobicistat, darunavir, emtricitabine, and tenofovir-Propantheline Bromide
- Propafenone-Cobicistat, elvitegravir, emtricitabine, and tenofovir
- Propafenone-Cobimetinib
- Propafenone-Cobimetinib Fumarate
- Propafenone-Cobolin-M injection
- Propafenone-Cocaine (Topical)
- Propafenone-Cocet Plus